Vanderbilt-Ingram Cancer Center Patient First for New Cell Engineering Platform

VICC is the first cancer center to enroll a patient in a clinical trial for this new technology developed by SQZ Biotechnologies of Watertown, Massachusetts. The investigational product is generated from the company’s technology that uses high-speed cell deformation to squeeze cells, creating a temporary disruption of their membranes and offering a window for the insertion of tumor antigens.

Read more

Moffitt Researchers Identify a Mechanism Controlling Tumor Cell Recognition by Immune Cells

Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma. However, tumors can escape immune cell detection even with the use of immunotherapies. In a new study published in Cancer Immunology Research, Moffitt Cancer Center researchers, in collaboration with the University of Miami’s Miller School of Medicine, describe a cellular mechanism that controls tumor cell recognition by immune cells.

Read more

University of Chicago scientists unveil the secret of cancer-associated Warburg effect

A new study, led by researchers at the University of Chicago, provides an answer to why cancer cells consume and use nutrients differently than their healthy counterparts and how that difference contributes to their survival and growth.

Read more

Blocking a Hormone’s Action in Immune Cells May Reduce Heart Disease Risk

Blocking the mineralocorticoid receptor (MR)—a protein that helps maintain normal levels of salt and water in the body—in immune cells may help reduce the risk of heart attack and stroke by improving blood vessel health. The study will be presented today at the American Physiological Society (APS) Aldosterone and ENaC in Health and Disease: The Kidney and Beyond Conference in Estes Park, Colo.

Read more